Free tool
FAERS Monitor: Bromsite
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 206911 or its brand name (Bromsite, Bromfenac Sodium). Reports on generic versions are filed under their own applications.
Reports
1,020
Serious
301
30% of reports
Hospitalization
101
Death reported
10
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- treatment failure146
- product packaging quantity issue76
- off label use75
- product dose omission issue69
- drug ineffective64
- eye pain63
- eye irritation58
- product storage error39
- product use issue36
- visual impairment29
- ocular hyperaemia28
- product quality issue28
- fatigue27
- poor quality product administered27
- vision blurred27
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2006 | 1 |
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 3 |
| 2011 | 2 |
| 2012 | 17 |
| 2013 | 7 |
| 2014 | 8 |
| 2015 | 17 |
| 2016 | 11 |
| 2017 | 88 |
| 2018 | 105 |
| 2019 | 78 |
| 2020 | 261 |
| 2021 | 73 |
| 2022 | 57 |
| 2023 | 75 |
| 2024 | 83 |
| 2025 | 63 |
| 2026 | 69 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,139 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| product packaging quantity issueSignal | 76 | 139.6 | 112.4 | 10,258 |
| poor quality product administeredSignal | 27 | 53.0 | 36.5 | 1,322 |
| treatment failureSignal | 146 | 36.4 | 31.3 | 5,002 |
| eye painSignal | 63 | 23.0 | 18.1 | 1,309 |
| eye irritationSignal | 58 | 20.8 | 16.2 | 1,075 |
| ocular hyperaemiaSignal | 28 | 12.2 | 8.4 | 277 |
| product storage errorSignal | 39 | 9.2 | 6.8 | 278 |
| product dose omission issueSignal | 69 | 4.8 | 3.9 | 209 |
| visual impairmentSignal | 29 | 4.8 | 3.4 | 85 |
| product quality issueSignal | 28 | 4.3 | 3.0 | 67 |
| vision blurredSignal | 27 | 4.1 | 2.8 | 60 |
| product use issueSignal | 36 | 4.0 | 2.9 | 77 |
| off label use | 75 | 1.8 | 1.4 | 25 |
| drug ineffective | 64 | 1.0 | 0.8 | 0 |
| fatigue | 27 | 0.7 | 0.5 | 3 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.